Gossamer Bio, Inc. (GOSS)
0.1999
+0.02
(+14.23%)
USD |
NASDAQ |
Aug 25, 12:14
Gossamer Bio EPS Diluted (Quarterly) : -0.0766 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0766 |
| March 31, 2026 | -0.1993 |
| December 31, 2025 | -0.2085 |
| September 30, 2025 | -0.2115 |
| June 30, 2025 | -0.1684 |
| March 31, 2025 | -0.1615 |
| December 31, 2024 | -0.1458 |
| September 30, 2024 | -0.1361 |
| June 30, 2024 | 0.2064 |
| March 31, 2024 | -0.1857 |
| December 31, 2023 | -0.2136 |
| September 30, 2023 | -0.2074 |
| June 30, 2023 | -0.4452 |
| March 31, 2023 | -0.5182 |
| December 31, 2022 | -0.5915 |
| September 30, 2022 | -0.651 |
| June 30, 2022 | -0.7365 |
| March 31, 2022 | -0.7614 |
| Date | Value |
|---|---|
| December 31, 2021 | -0.7446 |
| September 30, 2021 | -0.8033 |
| June 30, 2021 | -0.8012 |
| March 31, 2021 | -0.778 |
| December 31, 2020 | -0.8824 |
| September 30, 2020 | -0.8002 |
| June 30, 2020 | -1.004 |
| March 31, 2020 | -0.8737 |
| December 31, 2019 | -0.8926 |
| September 30, 2019 | -0.7983 |
| June 30, 2019 | -0.7384 |
| March 31, 2019 | -0.898 |
| December 31, 2018 | -0.5889 |
| September 30, 2018 | -0.7501 |
| June 30, 2018 | -0.4969 |
| March 31, 2018 | -0.3952 |
| December 31, 2017 | -0.0979 |
| September 30, 2017 | -0.0044 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| United Therapeutics Corp. | 7.271 |
| Arbutus Biopharma Corp. | -0.026 |
| Kura Oncology, Inc. | -0.769 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 16.90M |
| Revenue (Quarterly) | 9.238M |
| Total Expenses (Quarterly) | -7.662M |
| Enterprise Value | 68.59M |
| Gross Profit Margin (Quarterly) | 97.27% |
| Earnings Yield | -348.1% |
| Normalized Earnings Yield | -389.39 |